Olema updates early data for breast cancer therapy
unomat/iStock via Getty Images
- Olema Pharmaceuticals (NASDAQ:OLMA) added ~3% on Thursday after the oncology-focused biotech announced interim results for its lead asset OP-1250 from a Phase 1b/2 clinical study in patients with breast cancer.
- According to the company, data as of March 08 indicated that OP-1250 was safe and well tolerated up to 120 mg dose in combination with CDK4/6 inhibitor palbociclib in patients with ER+/HER2- breast cancer.
- Out of 29 patients who had received the therapy at different dose levels, including 120 mg, the Recommended Phase 2 Dose, five patients have indicated partial responses, including one confirmed response as of the data cut.
- The data presented at a medical event on Thursday further showed that 59% of patients continue to undergo the treatment while additional enrollments are ongoing.
- “The findings presented today support the potential for OP-1250 to become a best-in-class endocrine therapy in the first-line treatment of ER+/HER2- metastatic breast cancer,” Chief Executive of OLMA Sean Bohen remarked.